Comparative Pharmacology
Head-to-head clinical analysis: FAYOSIM versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAYOSIM versus ZADITOR.
FAYOSIM vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
10 mg orally once daily
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine
Antihistamine